Literature DB >> 11744838

HIV-1-related morbidity in adults, Abidjan, Côte d'Ivoire: a nidus for bacterial diseases.

A Attia1, C Huët, X Anglaret, S Toure, T Ouassa, G Gourvellec, H Menan, N Dakoury-Dogbo, P Combe, G Chêne, T N'Dri-Yoman, R Salamon.   

Abstract

We studied mortality and morbidity in 270 HIV-1-infected adults (60% women, median age 31 years, mean baseline CD4 count 331/mm(3) ) observed in a follow-up that lasted a median 10 months in Côte d'Ivoire. Survival and probability of remaining free from any episode of morbidity at 12 months were 0.80 and 0.50, respectively. Baseline CD4 count <200/mm(3) was the only variable associated with global morbidity and mortality, with hazard ratios of 2.50 and 7.57, respectively. The most frequent causes of morbidity were severe bacterial infections (incidence rate: 26.1 per 100 person-years [py]), followed by oral candidiasis (22.3% py), unexplained weight loss over 10% of baseline body weight (13.3% py), tuberculosis (10.1% py), unexplained chronic diarrhea (9.7% py), and isosporiasis (5.1% py). Nontyphoid Salmonella accounted for 37% of isolated strains during severe bacterial infections, followed by Streptococcus pneumoniae (34%), Escherichia coli (15%), and Shigella species (7%). A significant part of bacterial morbidity occurred in patients with baseline CD4 count > or = 200/mm(3), in whom the incidence rate of bacterial diseases was 21.3% py and the probability of remaining free from any bacterial infection at 12 months was 0.80 (vs. 36.4% py and 0.71 in patients with baseline CD4 count <200/mm(3); p =.07).

Entities:  

Mesh:

Year:  2001        PMID: 11744838     DOI: 10.1097/00042560-200112150-00012

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  7 in total

1.  Evaluation of 17 medicinal plants from Northern Côte d'Ivoire for their in vitro activity against Streptococcus pneumoniae.

Authors:  W Mamidou Koné; K Kamanzi Atindehou; A Kacou-N'douba; M Dosso
Journal:  Afr J Tradit Complement Altern Med       Date:  2006-08-28

2.  Determinants of early and late mortality among HIV-infected individuals receiving home-based antiretroviral therapy in rural Uganda.

Authors:  David M Moore; Constantin T Yiannoutsos; Beverly S Musick; Jordan Tappero; Richard Degerman; James Campbell; Willy Were; Frank Kaharuza; Lorraine N Alexander; Robert Downing; Jonathan Mermin
Journal:  J Acquir Immune Defic Syndr       Date:  2011-11-01       Impact factor: 3.731

3.  Estimates of opportunistic infection incidence or death within specific CD4 strata in HIV-infected patients in Abidjan, Côte d'Ivoire: impact of alternative methods of CD4 count modelling.

Authors:  Sylvie Deuffic-Burban; Elena Losina; Bingxia Wang; Delphine Gabillard; Eugène Messou; Nomita Divi; Kenneth A Freedberg; Xavier Anglaret; Yazdan Yazdanpanah
Journal:  Eur J Epidemiol       Date:  2007-09-08       Impact factor: 8.082

4.  Modeling HIV transmission risk among Mozambicans prior to their initiating highly active antiretroviral therapy.

Authors:  C R Pearson; A E Kurth; S Cassels; D P Martin; J M Simoni; P Hoff; E Matediana; S Gloyd
Journal:  AIDS Care       Date:  2007-05

5.  High prevalence of tuberculosis and serious bloodstream infections in ambulatory individuals presenting for antiretroviral therapy in Malawi.

Authors:  Richard A Bedell; Suzanne T B Anderson; Monique van Lettow; Ann Akesson; Elizabeth L Corbett; Moses Kumwenda; Adrienne K Chan; Robert S Heyderman; Rony Zachariah; Anthony D Harries; Andrew R Ramsay
Journal:  PLoS One       Date:  2012-06-22       Impact factor: 3.240

Review 6.  Getting to zero HIV deaths: progress, challenges and ways forward.

Authors:  Nathan Ford; Marco Vitoria; Gottfried Hirnschall; Meg Doherty
Journal:  J Int AIDS Soc       Date:  2013-12-01       Impact factor: 5.396

Review 7.  Disparities in the Magnitude of Human Immunodeficiency Virus-related Opportunistic Infections Between High and Low/Middle-income Countries: Is Highly Active Antiretroviral Therapy Changing the Trend?

Authors:  M O Iroezindu
Journal:  Ann Med Health Sci Res       Date:  2016 Jan-Feb
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.